Antiviral Chemistry and Chemotherapy

Aims & Scope

Antiviral Chemistry & Chemotherapy is a peer-reviewed, open access journal that publishes research on all aspects of antiviral compounds, including their chemistry, therapeutic effects, biochemistry, pharmacology, mode of action and virology.

The journal also publishes reviews, pointers, short communications, protocols and correspondence.

Original research manuscripts are required to present rigorous and reproducible scientific methodologies, and a clear antiviral design rationale to be considered for publication.

Manuscripts that report negative results are welcome as long as they conform to the above publication criteria.

View Aims & Scope

---

Metrics & Ranking

Journal Rank

Year	Value
2024	15877

Journal Citation Indicator

Year	Value
2024	23

SJR (SCImago Journal Rank)

Year	Value
2024	0.325

Quartile

Year	Value
2024	Q3

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Immunology and Microbiology, Medicine and Pharmacology, Toxicology and Pharmaceutics, designed to support cutting-edge academic discovery.

---

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Cytokines and HIV-1: Interactions and Clinical Implications

  Citation: 266

  Authors: Katherine, Suzanne M

• Regiospecific Synthesis and Anti-Human Immunodeficiency Virus Activity of Novel 5-Substituted <i>N</i>-Alkylcarbamoyl and <i>N,N</i>-Dialkyl Carbamoyl 1,2,3-Triazole-TSAO Analogues

  Citation: 219

  Authors: S, R, C, F, E, J, M-J

• HPMPC (cidofovir), PMEA (adefovir) and Related Acyclic Nucleoside Phosphonate Analogues: A Review of their Pharmacology and Clinical Potential in the Treatment of Viral Infections

  Citation: 199

  Authors: L, R, G, J, J, E

• Amino Acid Ester Prodrugs of Acyclovir

  Citation: 190

  Authors: L. M., G. F., P., T., T. A.

• Structural Features and Antiviral Activity of Sulphated Fucans from the Brown Seaweed <i>Cystoseira Indica</i>

  Citation: 176

  Authors: Pinaki, Cecilia Gabriela, Kausik, Carlos Alberto, Elsa Beatriz, Bimalendu

• Evaluation of Immunomodulators, Interferons and Known <i>in Vitro</i> SARS-CoV Inhibitors for Inhibition of SARS-Cov Replication in BALB/c Mice

  Citation: 173

  Authors: Dale L, Craig W, Kevin, Matthew, Robert, Larry, Paul KS, Robert W

• Nanoparticulate Delivery Systems for Antiviral Drugs

  Citation: 161

  Authors: David, Roberta

• Famciclovir and Penciclovir. The Mode of Action of Famciclovir Including Its Conversion to Penciclovir

  Citation: 153

  Authors: R. A. Vere

• Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration

  Citation: 134

  Authors: Erik

• Inhibition of Severe Acute Respiratory Syndrome-Associated Coronavirus (SARSCoV) by Calpain Inhibitors and β-D-N⁴-Hydroxycytidine

  Citation: 129

  Authors: Dale L, Valerie D, Jared, Donald F, John D, Michael J, Robert W

---